Is ACADIA Pharmaceuticals Inc (ACAD) overvalued? · P/E 15, rev $957.8M
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
This page asks whether ACADIA Pharmaceuticals Inc (ACAD) looks expensive on cached numbers — not a short thesis.
Latest reported ACAD revenue for 2024-12-31 was $957.8M. Net income was $226.5M. Revenue was up 314.6% from 2023-12-31 to 2024-12-31. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ACAD 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ACAD stock page for the full model, not this heading.
Not investment advice.